5 June 2019 - Pfizer is fighting back against a report that it hid the potential of a blockbuster drug to prevent Alzheimer’s disease in order to avoid shelling out for a “costly clinical trial.”

Researchers at Pfizer in 2015 found that Enbrel, an anti-inflammatory drug used to treat rheumatoid arthritis, seemed to reduce the risk of Alzheimer’s disease by 64 percent, the Washington Post reported Tuesday.

But a clinical trial on 3,000 to 4,000 patients to test the hypothesis would have cost about $80 million, according to research prepared by Pfizer’s inflammation and immunology department and seen by the Washington Post.

Read New York Post article